Institute of Nano Electronic Engineering, Universiti Malaysia Perlis, 01000 Kangar, Perlis, Malaysia.
Faculty of Chemical Engineering Technology, Universiti Malaysia Perlis, 02600 Arau, Perlis, Malaysia.
Crit Rev Anal Chem. 2022;52(7):1511-1523. doi: 10.1080/10408347.2021.1890543. Epub 2021 Jun 7.
The importance of nanotechnology in medical applications especially with biomedical sensing devices is undoubted. Several medical diagnostics have been developed by taking the advantage of nanomaterials, especially with electrical biosensors. Biosensors have been predominantly used for the quantification of different clinical biomarkers toward detection, screening, and follow-up the treatment. At present, ovarian cancer is one of the severe complications that cannot be identified until it becomes most dangerous as the advanced stage. Based on the American Cancer Society, 20% of cases involved in the detection of ovarian cancer are diagnosed at an early stage and 80% diagnosed at the later stages. The patient just has a common digestive problem and stomach ache as early symptoms and people used to ignore these symptoms. Micro ribonucleic acid (miRNA) is classified as small non-coding RNAs, their expressions change due to the association of cancer development and progression. This article reviews and discusses on the currently available strategies for the early detection of ovarian cancers using miRNA as a biomarker associated with electrical biosensors. A unique miRNA-based biomarker detections are specially highlighted with biosensor platforms to diagnose ovarian cancer.
纳米技术在医学应用中的重要性，尤其是在生物医学传感设备方面，是毋庸置疑的。已经开发出了几种利用纳米材料的医学诊断方法，特别是利用电子生物传感器。生物传感器主要用于定量检测不同的临床生物标志物，以进行检测、筛查和跟踪治疗。目前，卵巢癌是一种严重的并发症，直到发展到晚期才会被发现。根据美国癌症协会的数据，20%的卵巢癌病例是在早期发现的，而 80%是在晚期发现的。患者早期只有常见的消化问题和胃痛等症状，人们通常会忽略这些症状。微核糖核酸（miRNA）被归类为小非编码 RNA，由于癌症的发生和发展，其表达会发生变化。本文综述和讨论了目前使用 miRNA 作为与电子生物传感器相关的生物标志物来早期检测卵巢癌的方法。本文特别强调了基于 miRNA 的生物标志物检测方法与生物传感器平台相结合，用于诊断卵巢癌。
